Stock TSHA TAYSHA GENE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Real-time Estimate Cboe BZX
Other stock markets
 10:35:42 2024-04-30 am EDT 		5-day change 1st Jan Change
2.445 USD -0.20% Intraday chart for Taysha Gene Therapies, Inc. -2.37% +39.55%
Apr. 09 Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target MT
Mar. 21 Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
MT
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue
MT
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
CI
Taysha Gene Therapies Gets Expanded Eligibility in Canada for Early Trial of Rett Syndrome Treatment
MT
Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
CI
Taysha Gene Therapies Q3 Net Loss Widens Unexpectedly
MT
Earnings Flash (TSHA) TAYSHA GENE THERAPIES Posts Q3 Revenue $4.75M
MT
Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy 30th Annual Congress
CI
Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
CI
Taysha to End TSHA-120 Program in Giant Axonal Neuropathy; Shares Down After-Hours
MT
Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy
CI
Taysha Gene Therapies Shares Rise as Company Regains Compliance With Nasdaq Listing Rules
MT
Taysha Gene Therapies Secures FDA Fast Track Designation for Rett Syndrome Treatment; Shares Rise
MT
Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
CI
Paul B Manning acquired an additional 25.4% stake in Taysha Gene Therapies, Inc. for $14.82 million.
CI
Taysha Gene Therapies Shares Up 120% Following Initial Data From Candidate Trial, Regulatory Updates
MT
Taysha Gene Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Taysha Gene Therapies Recommended to Continue Trial in Rett Syndrome
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSHA Stock
  4. News Taysha Gene Therapies, Inc.
  5. Highlights